Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 1
2014 2
2015 1
2016 3
2017 3
2018 4
2019 3
2020 3
2021 5
2022 5
2023 4
2024 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

27 results

Results by year

Filters applied: . Clear all
Page 1
Phase 1/2a clinical trial in ALS with ropinirole, a drug candidate identified by iPSC drug discovery.
Morimoto S, Takahashi S, Ito D, Daté Y, Okada K, Kato C, Nakamura S, Ozawa F, Chyi CM, Nishiyama A, Suzuki N, Fujimori K, Kondo T, Takao M, Hirai M, Kabe Y, Suematsu M, Jinzaki M, Aoki M, Fujiki Y, Sato Y, Suzuki N, Nakahara J; Pooled Resource Open-Access ALS Clinical Trials Consortium; Okano H. Morimoto S, et al. Cell Stem Cell. 2023 Jun 1;30(6):766-780.e9. doi: 10.1016/j.stem.2023.04.017. Cell Stem Cell. 2023. PMID: 37267913 Free article. Clinical Trial.
The natural history of ALS: Baseline characteristics from a multicenter clinical cohort.
Berger A, Locatelli M, Arcila-Londono X, Hayat G, Olney N, Wymer J, Gwathmey K, Lunetta C, Heiman-Patterson T, Ajroud-Driss S, Macklin EA, Bind MA, Goslin K, Stuchiner T, Brown L, Bazan T, Regan T, Adamo A, Ferment V, Schroeder C, Somers M, Manousakis G, Faulconer K, Sinani E, Mirochnick J, Yu H, Sherman AV, Walk D; Pooled Resource Open-Access ALS Clinical Trials Consortium. Berger A, et al. Amyotroph Lateral Scler Frontotemporal Degener. 2023 Jul 17:1-9. doi: 10.1080/21678421.2023.2232812. Online ahead of print. Amyotroph Lateral Scler Frontotemporal Degener. 2023. PMID: 37461167
Item response theory analysis of the Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised in the Pooled Resource Open-Access ALS Clinical Trials Database.
Bacci ED, Staniewska D, Coyne KS, Boyer S, White LA, Zach N, Cedarbaum JM; Pooled Resource Open-Access ALS Clinical Trials Consortium. Bacci ED, et al. Amyotroph Lateral Scler Frontotemporal Degener. 2016;17(3-4):157-67. doi: 10.3109/21678421.2015.1095930. Epub 2015 Oct 16. Amyotroph Lateral Scler Frontotemporal Degener. 2016. PMID: 26473473
Predicting dysphagia onset in patients with ALS: the ALS dysphagia risk score.
Perry BJ, Nelson J, Wong JB, Kent DM; Pooled Resource Open-Access ALS Clinical Trials Consortium. Perry BJ, et al. Amyotroph Lateral Scler Frontotemporal Degener. 2022 May;23(3-4):271-278. doi: 10.1080/21678421.2021.1961805. Epub 2021 Aug 10. Amyotroph Lateral Scler Frontotemporal Degener. 2022. PMID: 34375156 Free PMC article.
"ALS reversals": demographics, disease characteristics, treatments, and co-morbidities.
Harrison D, Mehta P, van Es MA, Stommel E, Drory VE, Nefussy B, van den Berg LH, Crayle J, Bedlack R; Pooled Resource Open-Access ALS Clinical Trials Consortium. Harrison D, et al. Amyotroph Lateral Scler Frontotemporal Degener. 2018 Nov;19(7-8):495-499. doi: 10.1080/21678421.2018.1457059. Epub 2018 Apr 2. Amyotroph Lateral Scler Frontotemporal Degener. 2018. PMID: 29607695
27 results